The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Open accessAbstract
// Anna Passarelli 1 , Francesco Mannavola 1 , Luigia Stefania Stucci 1 , Marco Tucci 1 and Francesco Silvestris 1 1 Department of Biomedical Sciences and Human Oncology, University of Bari ‘Aldo Moro’, Bari, Italy Correspondence to: Anna Passarelli, email: passarellian@libero.it Keywords: melanoma; immune system; immunogenicity; immunoediting; immune escape Received: May 26, 2017 Accepted: September 21, 2017 Published: October 31, 2017 ABSTRACT Melanoma is one of the most immunogenic tumors and its relationship with host immune system is currently under investigation. Many immunomodulatory mechanisms, favoring melanomagenesis and progression, have been described to interfere with the disablement of melanoma recognition and attack by immune cells resulting in immune resistance and immunosuppression. This knowledge produced therapeutic advantages, such as immunotherapy, aiming to overcome the immune evasion. Here, we review the current advances in cancer immunoediting and focus on melanoma immunology, which involves a dynamic interplay between melanoma and immune system, as well as on effects of “targeted therapies” on tumor microenvironment for combination strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Stimpfel, M., & Virant-Klun, I. (2016) · Journal of Cancer Stem Cell Research · doi:10.14343/jcscr.2016.4e1003 · Cited by 2,540
Nasir, O. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Regulation of Cutaneous Malignancy by γδ T Cells
Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P., Sutton, B., Tigelaar, R. E., & Hayday, A. C. (2001) · Science · doi:10.1126/science.1063916 · Cited by 1,004
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
Scanlan., M. J., Gure., A. O., Jungbluth., A. A., Old., L. J., & Chen., Y. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18803.x · Cited by 873
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Tim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M., Konto, C., & Wolchok, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 714
NRAS mutation status is an independent prognostic factor in metastatic melanoma
Jakob, J. A., Bassett, R. L., Ng, C. S., Curry, J. L., Joseph, R. W., Alvarado, G. C., Rohlfs, M. L., Richard, J., Gershenwald, J. E., Kim, K. B., et al. (2012) · Cancer · doi:10.1002/cncr.26724 · Cited by 689
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Inflammatory Cytokines Provide a Third Signal for Activation of Naive CD4+ and CD8+ T Cells
Curtsinger, J. M., Schmidt, C. S., Mondino, A., Lins, D. C., Kedl, R. M., Jenkins, M. K., & Mescher, M. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3256 · Cited by 616
Origin and development of dendritic cells
Liu, K., & Nussenzweig, M. C. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00879.x · Cited by 543
VISTA is an immune checkpoint molecule for human T cells
Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S., Suriawinata, A. A., Yan, S., Ernstoff, M. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1504 · Cited by 510
Muul, L. M., Spiess, P. J., Director, E. P., & Rosenberg, S. A. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.989 · Cited by 486
The determinants of tumour immunogenicity
Blankenstein, T., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3246 · Cited by 441
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1510353 · Cited by 426
Epitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., & Raulet, D. H. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 394
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., & Kroemer, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1316 · Cited by 380
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36022 · Cited by 347 · cited 2×
“In particular, they recognize and attack melanoma cells expressing low MHC class-I molecules with higher efficiency then T-cells [39] and promote functional interactions between the natural cytotoxicity receptors as NKG2D, NKp30, NKp44, NKp46 and relative ligands expressed by malignant cells [40].”
BackgroundLong, G. V., Grob, J.-J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Lane, S. R., Mak, C., Legenne, P., Flaherty, K. T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30578-2 · Cited by 315
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., & Lotze, M. T. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118958 · Cited by 289
Tumour progression and the nature of cancer
Clark, W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.375 · Cited by 282
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Kruse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 270
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs, J. F., Nierkens, S., Figdor, C. G., de Vries, I. J. M., & Adema, G. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70155-3 · Cited by 245
The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 245
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
Champiat, S., Ferté, C., Lebel-Binay, S., Eggermont, A., & Soria, J. C. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 192
Seliger, B., Ritz, U., Abele, R., Bock, M., Tampé, R., Sutter, G., Drexler, I., Huber, C., & Ferrone, S. (2001) · PubMed · Cited by 189
Schurich, A., Pallett, L. J., Lubowiecki, M., Singh, H. D., Gill, U. S., Kennedy, P. T., Nastouli, E., Tanwar, S., Rosenberg, W., & Maini, M. K. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003208 · Cited by 186
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo
Cormier, J. N., Hijazi, Y. M., Abati, A., Fetsch, P., Bettinotti, M., Steinberg, S. M., Rosenberg, S. A., & Marincola, F. M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980209)75:4<517::aid-ijc5>3.0.co;2-w · Cited by 173
Merelli, B., Massi, D., Cattaneo, L., & Mandalà, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.002 · Cited by 170
Romero, P., Valmori, D., Pittet, M. J., Zippelius, A., Rimoldi, D., Lévy, F., Dutoit, V., Ayyoub, M., Rubio‐Godoy, V., Michielin, O., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18808.x · Cited by 164
Jordan, K. R., Amaria, R. N., Ramirez, O., Callihan, E., Gao, D., Borakove, M., Manthey, E., Borges, V. F., & McCarter, M. D. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1475-x · Cited by 144
Kono, M., Dunn, I. S., Durda, P. J., Butera, D., Rose, L. B., Haggerty, T. J., Benson, E. M., & Kurnick, J. T. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0077 · Cited by 141
The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells
Wehner, R., Dietze, K., Bachmann, M. P., & Schmitz, M. (2011) · Journal of Innate Immunity · doi:10.1159/000323923 · Cited by 134
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
Schilling, B., Sucker, A., Griewank, K., Zhao, F., Weide, B., Görgens, A., Giebel, B., Schadendorf, D., & Paschen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28168 · Cited by 124
Mechanisms of local immunosuppression in cutaneous melanoma
Polak, M. E., Borthwick, N., Gabriel, F. G., Johnson, P., Higgins, B., Hurren, J., McCormick, D., Jager, M. J., & Cree, I. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603763 · Cited by 117
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Palmieri, G., Ombra, M. N., Colombino, M., Casula, M., Sini, M. C., Manca, A., Paliogiannis, P., Ascierto, P. A., & Cossu, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00183 · Cited by 110
Ott, P. A., Henry, T., Baranda, S. J., Frleta, D., Manches, O., Bogunovic, D., & Bhardwaj, N. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1389-z · Cited by 107
Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105
Garrido, F., Algarra, I., & Garcia-Lora, A. M. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0893-2 · Cited by 102
Cytokine-Mediated Programmed Proliferation of Virus-Specific CD8+ Memory T Cells
Raué, H.-P., Beadling, C., Haun, J., & Slifka, M. K. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.019 · Cited by 91
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.
Kim, T. S., Amaria, R. N., Spencer, C. N., Reuben, A., Cooper, Z. A., & Wargo, J. A. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.04.002 · Cited by 77
Bachmayr-Heyda, A., Aust, S., Heinze, G., Polterauer, S., Grimm, C., Braicu, E. I., Sehouli, J., Lambrechts, S., Vergote, I. B., Mahner, S., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-422 · Cited by 71
Mutations of theBRAFgene in human cancer, by Davieset al. (Nature2002; 417: 949-54)
Millington, G. W. M. (2013) · Clinical and Experimental Dermatology · doi:10.1111/ced.12015 · Cited by 69
Straten, P. T., Guldberg, P., Grønbæk, K., Hansen, M. R., Kirkin, A. F., Seremet, T., Zeuthen, J., & Becker, J. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.443 · Cited by 66
Farley, T., Mandava, N., Prall, F. R., & Carsky, C. (2008) · The Annals of Family Medicine · doi:10.1370/afm.857 · Cited by 60
Densely Granulated Murine NK Cells Eradicate Large Solid Tumors
Liu, R. B., Engels, B., Arina, A., Schreiber, K., Hyjek, E. M., Schietinger, A., Binder, D. C., Butz, E. A., Krausz, T. N., Rowley, D. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3208 · Cited by 59
Cancer-Immune Equilibrium: Questions Unanswered
Bhatia, A., & Kumar, Y. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0065-8 · Cited by 55
The immune escape in melanoma: role of the impaired dendritic cell function
Tucci, M., Stucci, L. S., Passarelli, A. M., Giudice, G., Dammacco, F., & Silvestris, F. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.955851 · Cited by 55
Self-citationKazandjian, D. G., Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S. W., Libeg, M., Kluetz, P. G., Sridhara, R., Keegan, P., & Pazdur, R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3934 · Cited by 53
Failli, A., Legitimo, A., Orsini, G., Romanini, A., & Consolini, R. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.013 · Cited by 46
miRNAs in melanoma: a defined role in tumor progression and metastasis
Mannavola, F., Tucci, M., Felici, C., Stucci, L. S., & Silvestris, F. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1100965 · Cited by 45
Self-citationHow melanoma cells inactivate NK cells
Pietra, G., Vitale, M., Moretta, L., & Mingari, M. C. (2012) · OncoImmunology · doi:10.4161/onci.20405 · Cited by 38
Epigenetics Meets Immune Checkpoints
Covre, A., Coral, S., Giacomo, A. M. D., Taverna, P., Azab, M., & Maio, M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.003 · Cited by 31
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci84828 · Cited by 17
Tel, J., Koornstra, R., de Haas, N., van Deutekom, V., Westdorp, H., Boudewijns, S., van Erp, N., Blasio, S. D., Gerritsen, W. R., Figdor, C. G., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0844-6 · Cited by 13
BRAF-inhibition and tumor immune suppression
Steinberg, S. M., & Turk, M. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.988039 · Cited by 8
Cited by
Current state of melanoma diagnosis and treatment
Davis, L. E., Shalin, S. C., & Tackett, A. J. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1640032 · Cited by 922
Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
Marzagalli, M., Ebelt, N. D., & Manuel, E. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.002 · Cited by 345
Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface
Hunter, M. V., Moncada, R., Weiss, J. M., Yanai, I., & White, R. M. (2021) · Nature Communications · doi:10.1038/s41467-021-26614-z · Cited by 285
Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
Stanton, D. N., Ganguli-Indra, G., Indra, A. K., & Karande, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020319 · Cited by 22
Metadata
- Authors
- Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-10-31
- Volume
- 8
- Issue
- 62
- Pages
- 106132-106142
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2766512176
- Cited by
- 275
- References
- 104
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.